Sign in Membership
Pricing & Procurement Governance

China’s 2026 Dual-List Draft Workplan: Earlier Innovation Access, Tighter Lifecycle Pricing Discipline

China’s 2026 NRDL draft workplan signals a more integrated, lifecycle-oriented reimbursement framework: earlier access for innovative therapies, closer regulatory–reimbursement alignment anchored in RWE, and tighter pricing discipline for mature and me-too products.

On May 9, the National Healthcare Security Administration released the 2026 Workplan for the Adjustment of the National Reimbursement Drug List (NRDL), Maternity Insurance, Work Injury Insurance Drug List, and the Commercial Health Insurance Innovative Drug List (Draft for Public Comment).

Compared with previous years, the 2026 NRDL adjustment timeline has been moved forward by roughly one month to allow more time for post-listing implementation, hospital rollout, and coordination with commercial health insurance following publication of the final catalogues.

The draft workplan also introduces several important updates spanning reimbursement application windows, conditional approval drugs, renewal and routine management rules, the new generic replacement pathway, and non-exclusive competitive bidding rules.

Taken together, these changes point toward several emerging trends within China’s evolving reimbursement framework: closer alignment between regulatory approval and reimbursement access, increasingly anchored in real-world evidence generation and uncertainty management; deeper integration between the NRDL and commercial insurance pathways; more explicit lifecycle pricing governance linked to budget impact, competition, and real-world performance; and tighter pricing discipline for mature and me-too products.


You might also like...

Mar 12, 2026

RWE and the Quiet Rewiring of China’s Reimbursement System

Five recent policy releases show how real-world evidence is quietly reshaping pricing, reimbursement, and clinical adoption for both innovative and established medicines in China.
Feb 12, 2026

Three Shifts Reshaping China’s Drug Payment System: Implications for Global Pharma

China’s drug payment system is shifting from isolated policy levers toward an environment defined by their interaction. Recent signals are beginning to link pricing, launch timing, and multi-payer access in ways that materially change how global pharma approaches China.
Jan 14, 2026

From Reference Tool to Operating Model: A Roadmap for China’s C-List

China’s C-List establishes a national reference for innovative drugs outside the NRDL—but not yet a payment system. Its impact will hinge on whether insurers and regulators can turn policy intent into a workable, risk-sustainable commercial coverage model.
Dec 15, 2025

China Establishes Market-Price Database, Reshaping Global Pricing Signals

China’s new drug price database marks a subtle but important shift in price governance—separating how market prices are recorded from how reimbursement is negotiated. The change reshapes pricing signals in ways that matter for both domestic innovators and multinational firms.
Dec 03, 2025

China’s Biosimilar VBP: Emerging Rules, Pricing Dynamics, and What Early Signals Suggest

China’s VBP is shifting toward biosimilars, raising strategic questions for global manufacturers: Will the country cultivate an EU-style biosimilar market—and will VBP mirror generics or follow a modified path? This series interprets early policy signals to help companies prepare.